Your browser doesn't support javascript.
loading
Metformin synergistically enhances antiproliferative effects of cisplatin and etoposide in NCI-H460 human lung cancer cells / Metformina sinergicamente potencializa os efeitos antiproliferativos de cisplatina e etoposideo em linhagem de celulas de cancer humano de pulmao NCI-H460
Teixeira, Sarah Fernandes; Guimaraes, Isabella dos Santos; Madeira, Klesia Pirola; Daltoe, Renata Dalmaschio; Silva, Ian Victor; Rangel, Leticia Batista Azevedo.
  • Teixeira, Sarah Fernandes; Federal University of Espirito Santo. Vitoria. BR
  • Guimaraes, Isabella dos Santos; Federal University of Espirito Santo. Vitoria. BR
  • Madeira, Klesia Pirola; Federal University of Espirito Santo. Vitoria. BR
  • Daltoe, Renata Dalmaschio; Federal University of Espirito Santo. Vitoria. BR
  • Silva, Ian Victor; Federal University of Espirito Santo. Vitoria. BR
  • Rangel, Leticia Batista Azevedo; Federal University of Espirito Santo. Vitoria. BR
J. bras. pneumol ; 39(6): 644-649, Nov-Dec/2013. tab, graf
Article in English | LILACS | ID: lil-697780
ABSTRACT

OBJECTIVE:

To test the effectiveness of combining conventional antineoplastic drugs (cisplatin and etoposide) with metformin in the treatment of non-small cell lung cancer in the NCI-H460 cell line, in order to develop new therapeutic options with high efficacy and low toxicity.

METHODS:

We used the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and calculated the combination index for the drugs studied.

RESULTS:

We found that the use of metformin as monotherapy reduced the metabolic viability of the cell line studied. Combining metformin with cisplatin or etoposide produced a synergistic effect and was more effective than was the use of cisplatin or etoposide as monotherapy.

CONCLUSIONS:

Metformin, due to its independent effects on liver kinase B1, had antiproliferative effects on the NCI-H460 cell line. When metformin was combined with cisplatin or etoposide, the cell death rate was even higher. .
RESUMO

OBJETIVO:

Testar a eficácia da combinação terapêutica de antineoplásicos convencionais (cisplatina e etoposídeo) com metformina em linhagem celular NCI-H460 de câncer de pulmão não pequenas células, a fim de desenvolver novas possibilidades terapêuticas com eficácia superior e reduzida toxicidade.

MÉTODOS:

Foi utilizado o ensaio de brometo de 3-(4,5-dimetiltiazol-2-il)-2,5-difeniltetrazólio (MTT) e calculado o índice de combinação dos fármacos estudados.

RESULTADOS:

Observamos que o uso de metformina em monoterapia reduziu a viabilidade celular metabólica da linhagem de células estudada. O uso de metformina em combinação com cisplatina ou etoposídeo foi sinérgico e superior à monoterapia com cisplatina ou etoposídeo.

CONCLUSÕES:

A metformina, devido às suas ações independentes em liver kinase B1, apresentou atividade antiproliferativa na linhagem NCI-H460 e, em combinação com cisplatina ou etoposídeo, ampliou a taxa de morte celular. .
Subject(s)


Full text: Available Index: LILACS (Americas) Main subject: Cisplatin / Etoposide / Hypoglycemic Agents / Metformin / Antineoplastic Agents / Antineoplastic Agents, Phytogenic Limits: Humans Language: English Journal: J. bras. pneumol Journal subject: Pulmonary Disease (Specialty) Year: 2013 Type: Article Affiliation country: Brazil Institution/Affiliation country: Federal University of Espirito Santo/BR

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Index: LILACS (Americas) Main subject: Cisplatin / Etoposide / Hypoglycemic Agents / Metformin / Antineoplastic Agents / Antineoplastic Agents, Phytogenic Limits: Humans Language: English Journal: J. bras. pneumol Journal subject: Pulmonary Disease (Specialty) Year: 2013 Type: Article Affiliation country: Brazil Institution/Affiliation country: Federal University of Espirito Santo/BR